Skip to main content
. 2020 Aug 11;11(10):2812–2819. doi: 10.1111/1759-7714.13597

Figure 2.

Figure 2

(a) The analyses of progression‐free survival (PFS), overall survival (OS) and obective response rate (ORR) in patients receiving immune‐checkpoint inhibitor (ICI) combination therapy according to BoM. Progression‐free survival: Inline graphic, BoM‐; Inline graphic, BoM+. Overall survival: Inline graphic, BoM‐; Inline graphic, BoM+. Objective Response: Inline graphic, PD; Inline graphic, SD; Inline graphic, PR. (b) The analyses of PFS, OS and ORR in patients receiving ICI monotherapy according to BoM. Progression‐free survival: Inline graphic, BoM‐; Inline graphic, BoM+. Overall survival: Inline graphic, BoM‐; Inline graphic, BoM+. Objective Response: Inline graphic, PD; Inline graphic, SD; Inline graphic, PR.